The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
Launch of 20 new medicines expected by 2030
95.7% of patients responded to Breyanzi in the TRANSCEND FL trial
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Investing in Malaysia's largest clinic operator to expand the healthcare business
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Subscribe To Our Newsletter & Stay Updated
